Literature DB >> 30545922

Molecular analysis of a CD19-negative diffuse large B-cell lymphoma.

Lorric Delage1, Delphine Manzoni2, Charles Quinquenet3, Juliette Fontaine4, Alizée Maarek4, Kaddour Chabane2, Isabelle Mosnier2, Sandrine Hayette2, Evelyne Callet-Bauchu1,2, Beatrice Grange1,2, Adriana Plesa2, Pierre Sujobert5,2.   

Abstract

Entities:  

Year:  2018        PMID： 30545922      PMCID： PMC6395315          DOI： 10.3324/haematol.2018.203521

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

Review 2.  The biology and treatment of plasmablastic lymphoma.

Authors:  Jorge J Castillo; Michele Bibas; Roberto N Miranda
Journal:  Blood       Date:  2015-01-30       Impact factor: 22.113

Review 3.  CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas.

Authors:  Marcus P Watkins; Nancy L Bartlett
Journal:  Expert Opin Investig Drugs       Date:  2018-07-05       Impact factor: 6.206

4.  CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis.

Authors:  Elaine Y Chung; James N Psathas; Duonan Yu; Yimei Li; Mitchell J Weiss; Andrei Thomas-Tikhonenko
Journal:  J Clin Invest       Date:  2012-05-01       Impact factor: 14.808

5.  An antibody-deficiency syndrome due to mutations in the CD19 gene.

Authors:  Menno C van Zelm; Ismail Reisli; Mirjam van der Burg; Diana Castaño; Carel J M van Noesel; Maarten J D van Tol; Cristina Woellner; Bodo Grimbacher; Pablo J Patiño; Jacques J M van Dongen; José L Franco
Journal:  N Engl J Med       Date:  2006-05-04       Impact factor: 91.245

6.  Diminished expression of CD19 in B-cell lymphomas.

Authors:  Wei Yang; Neeta Agrawal; Jigar Patel; Alison Edinger; Ebenezer Osei; Dawn Thut; Jennifer Powers; Howard Meyerson
Journal:  Cytometry B Clin Cytom       Date:  2005-01       Impact factor: 3.058

7.  Tumor protein 53 mutations are enriched in diffuse large B-cell lymphoma with irregular CD19 marker expression.

Authors:  Marina Kazantseva; Noelyn A Hung; Sunali Mehta; Imogen Roth; Ramona Eiholzer; Alison M Rich; Benedict Seo; Margaret A Baird; Antony W Braithwaite; Tania L Slatter
Journal:  Sci Rep       Date:  2017-05-08       Impact factor: 4.379

8.  Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells.

Authors:  Xiaocui He; Kathrin Kläsener; Joseena M Iype; Martin Becker; Palash C Maity; Marco Cavallari; Peter J Nielsen; Jianying Yang; Michael Reth
Journal:  EMBO J       Date:  2018-04-18       Impact factor: 11.598

9.  CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.

Authors:  Kemeng Wang; Guoqing Wei; Delong Liu
Journal:  Exp Hematol Oncol       Date:  2012-11-29

10.  High-Grade B-Cell Neoplasm with Surface Light Chain Restriction and Tdt Coexpression Evolved in a MYC-Rearranged Diffuse Large B-Cell Lymphoma: A Dilemma in Classification.

Authors:  Dina Sameh Soliman; Ahmad Al-Sabbagh; Feryal Ibrahim; Ruba Y Taha; Zafar Nawaz; Sarah Elkourashy; Abdulrazzaq Haider; Susanna Akiki; Mohamed Yassin
Journal:  Case Rep Hematol       Date:  2017-08-13
View more
  1 in total

Review 1.  Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors.

Authors:  Sisi Zheng; Mukta Asnani; Andrei Thomas-Tikhonenko
Journal:  Cancer J       Date:  2019 May/Jun       Impact factor: 3.360
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.